Aushon, LightArray enter strategic partnership to provide multiplex biomarker products and services in China

NewsGuard 100/100 Score

Aushon BioSystems, Inc., a leading provider of multiplex immunoassay products and services for biomarker discovery, development and analysis announced during the ChinaTrials 2010 Summit in Beijing, China, that it has entered into a partnership with LightArray Biotech Company, Ltd., to provide Aushon's comprehensive suite of multiplex biomarker products and services to pharmaceutical, biotechnical, and academic research institutions located in mainland China.

“based in the Yangtze River Delta to serve the whole of China.”

LightArray operates a comprehensive drug development services laboratory in Wuxi, China and will now provide researchers with a local, centralized protein biomarker testing laboratory employing Aushon's protein biomarker technologies including:

  • A growing menu of 300+ validated assays
  • Multiplex biomarker sample testing service
  • Multiplex protein biomarker kits
  • Custom arrays and assay development
  • Array imaging and analysis systems

"Our strategic partnership with LightArray enables companies located in China and involved in pre-clinical and clinical research to take advantage of our full range of biomarker products and services, including our flexible sample testing service and growing menu of more than 300 biomarkers in key therapeutic areas such as oncology, inflammation, cardiovascular disease, and diabetes," said Pete Honkanen, CEO of Aushon. "They can also count on the same exacting level of reliability, performance and support that we deliver to our current customers in the United States, Europe and Southeast Asia."

"We are extremely excited by the opportunity to assist Aushon in bringing their portfolio of multiplex biomarker services and products into the emerging China market," said Alan Zhang, President and CEO of LightArray. "The adoption of biomarkers as a critical research tool in pre-clinical and clinical studies is growing rapidly in China, and our ability to provide local, regional access to the proven Aushon multiplex technology platform will be vital. We also look forward to providing the same unrivaled service and support to our customers that Aushon has built its reputation on."

Source:

Aushon BioSystems, Inc., and LightArray Biotech Company, Ltd.,

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Towards better diagnosis of neurodegenerative disorders: Skin biopsy for α-synuclein detection proves effective